Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 747-750, 2004; 10.1373/clinchem.2003.025353
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taxel, P.
Right arrow Articles by Raisz, L. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taxel, P.
Right arrow Articles by Raisz, L. G.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2004;50:747-750.)
© 2004 American Association for Clinical Chemistry, Inc.

Technical Briefs

Changes in Urinary Excretion of Helical Peptide during Therapy for Osteoporosis in Older Adults

Pamela Taxel1,3,a, Pamela M. Fall2, Karen M. Prestwood3, Lahta Dulipsingh4, Debrorah Dauser2, Christine Ohannessian2 and Lawrence G. Raisz1,2

1 Division of Endocrinology and Metabolism,2 General Clinical Research Center, and3 Department of Geriatrics, University of Connecticut Health Center, Farmington, CT;4 New Britain General Hospital, New Britain, CT

aauthor for correspondence: e-mail taxel@nso.uchc.edu

The first 300 words of the full text of this article appear below.

Bone is a dynamic tissue that is constantly undergoing remodeling or turnover, a requirement for maintenance of bone health. Our group and others have shown the usefulness of biochemical markers of bone turnover, specifically those that reflect bone resorption, in the evaluation of metabolic bone disease and the determination of response to treatment in the clinical as well as research setting (1)(2)(3).

Measurement of the degradation products of bone reflect the rate of bone turnover (2). Type 1 collagen, a triple helical molecule composed of two {alpha}1 chains and one {alpha}2 chain with cross-linking at the N- and C-telopeptides, comprises 90% of the organic matrix of bone (3). Degradation products of this molecule have been the most useful markers of bone resorption. During resorption of bone, type 1 collagen is cleaved by proteinases in both the helical and telopeptide regions. Initially markers were based on measurement of breakdown products of the cross-linked telopeptide region. Recently, a peptide consisting of residues 620–633 derived from the helical region of the {alpha}1 chain of type 1 collagen was isolated from the urine of patients with Paget disease of bone, and a competitive enzyme immunoassay for this peptide was developed (4)(5). We compared the changes in this new marker with changes in existing urinary markers, including N-telopeptide collagen cross-links (NTx), C-telopeptide collagen cross-links (CTx), and free deoxypyridinoline (DPD), from three different intervention studies in older men and women with osteoporosis.

We studied participants in three separate osteoporosis studies, each approved by the Institutional Review Board. Informed consent was obtained from each volunteer. Exclusion criteria were diseases known to affect bone metabolism; use of estrogen, androgens, corticosteroids, heparin, anticonvulsants, vitamin D (other than multivitamin), or calcitonin currently or in the past . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.